Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News

Improving CRC Screening Rates With High-Quality, Noninvasive Tests, with Keith Winfrey, MD, MPH Keith Winfrey, MD, MPH

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

ACP Urges Concern for Health Policy Issues, with Shari Erickson, MPH Shari Erickson, MPH

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

Reviving exhausted immune cells boosts tumor elimination

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Precision therapy could stop breast cancer at the source

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

What are the big unanswered questions about cancer? Experts discuss

Over the 40-year history of the University of Colorado Cancer Center, its investigators have answered many questions about cancer—what causes it, how to prevent it, and how to treat it. Those discoveries have helped many ...

Combination immunotherapy for rare cancers shows improved efficacy and survival rates

New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and difficult-to-treat cancers. The trial ...

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of ...

Over the 40-year history of the University of Colorado Cancer Center, its investigators have answered many questions about cancer—what causes it, how to prevent it, and how to treat it. Those discoveries have helped many ...

New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and difficult-to-treat cancers. The trial ...

News All Time

Mental and physical coaching before surgery prepares immune system and reduces complications, trial finds

The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need for rehabilitation to get back on their feet. But if patients improve their physical and mental ...

Flu vaccine performance varies by age, study reveals

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age ...

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see ...

Researchers aim to disrupt breast cancer line of communication and prevent spread

Cancer Center at Illinois (CCIL) Program Leader Erik Nelson's lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.

Study tracking how tumor microenvironment develops signals opportunity for early detection, risk prediction

Colorectal cancer precursor lesions are benign growths that can develop into colorectal cancer (CRC) over time, through either a conventional or serrated pathway. Understanding how the immune system reacts to these precursor ...

Rapid growth of radiopharmaceutical therapy highlights need for expertise

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining the education, training, and experience needed to ensure the safe and effective delivery of radiopharmaceutical therapy ...

Newly identified lymphoma subtype gives hope in fight against aggressive form of blood cancer

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer scientists and biologists ...

Blood test offers hope for more effective ovarian cancer treatment

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy.

Q&A: Connection between a distinct immune cell and colitis discovered

CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells exacerbate inflammation and lead to chronic disease in certain conditions.

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma ...

T cell therapies show long-term HPV gains

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center ...

Sleep issues linked to higher risk of severe asthma in children

About 30 to 40% of children with asthma experience sleep difficulties due to symptoms like coughing and wheezing. Poor sleep increases the risk of severe asthma exacerbations (attacks) that often necessitate a hospitalization ...

Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment ...

What is myasthenia gravis, the rare disease tennis great Monica Seles lives with?

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally.

Factoring in frailty and age could improve pancreatic cancer treatment

While some risk factors for cancer can be mitigated through lifestyle choices such as diet or exercise, aging is not one of them. In the case of pancreatic cancer, it also can limit treatment options if a patient is too frail ...

Unique immune signatures can distinguish rare autoimmune condition from multiple sclerosis

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's immune system mistakenly attacks the protective myelin sheath of nerve fibers in the central nervous ...

Recommended News For You

New tumor therapy approach reduces costs and side effects while increasing accessibility

Squeezing through tiny blood vessels may trigger melanoma cells to spread

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

Drug-chemo combo increases cancer treatment efficacy

Having a tattoo could increase your risk of developing lymphoma.

After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

Recommended Articles For You

The Power of White Blood Cells: How They Help Keep Us Healthy 

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA 

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Parkinson patient's gait is restored by a spinal cord stimulator.

2.

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

3.

Next Day Mood Is Affected by Ability to Recover From Work.

4.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

5.

Children with cancer experience much less pain at home when using a pain monitoring app.

1.

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients

2.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

3.

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma 

4.

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects 

5.

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

3.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

4.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot